MA26773A1 - Derives de 3-phenylpyridine et leur utilisation comme recepteurs antagonistes nk-1 - Google Patents

Derives de 3-phenylpyridine et leur utilisation comme recepteurs antagonistes nk-1

Info

Publication number: MA26773A1
Authority: MA; Morocco
Prior art keywords: phenylpyridine derivatives; antagonist receptors; antagonist; receptors; phenylpyridine
Prior art date: 1999-02-24

Application number

MA26301A

Other languages

English (en)

Inventor

Guido Galley

Patrick Schnider

Heinz Stadler

Torsten Hoffmann

Michael Boes

Walter Hunkeler

Thierry Godel

Original Assignee

Hoffmann La Roche

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-02-24

Filing date

2001-08-23

Publication date

2004-12-20

2001-08-23 Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche

2004-12-20 Publication of MA26773A1 publication Critical patent/MA26773A1/fr

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Pulmonology (AREA)
Addiction (AREA)
Vascular Medicine (AREA)
Heart & Thoracic Surgery (AREA)
Hospice & Palliative Care (AREA)
Ophthalmology & Optometry (AREA)
Cardiology (AREA)
Rheumatology (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Pyridine Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

MA26301A 1999-02-24 2001-08-23 Derives de 3-phenylpyridine et leur utilisation comme recepteurs antagonistes nk-1 MA26773A1 (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP99103503		1999-02-24

Publications (1)

Publication Number	Publication Date
MA26773A1 true MA26773A1 (fr)	2004-12-20

Family

ID=8237624

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA26301A MA26773A1 (fr)	1999-02-24	2001-08-23	Derives de 3-phenylpyridine et leur utilisation comme recepteurs antagonistes nk-1

Country Status (33)

Country	Link
US (1)	US6225316B1 (fr)
EP (1)	EP1157005B1 (fr)
JP (1)	JP4068305B2 (fr)
KR (1)	KR100437587B1 (fr)
CN (1)	CN1134417C (fr)
AR (1)	AR029616A1 (fr)
AT (1)	ATE280158T1 (fr)
AU (1)	AU772446B2 (fr)
BR (1)	BR0008494A (fr)
CA (1)	CA2364662C (fr)
CO (1)	CO5140087A1 (fr)
CZ (1)	CZ20013047A3 (fr)
DE (1)	DE60015089T2 (fr)
DK (1)	DK1157005T3 (fr)
ES (1)	ES2230070T3 (fr)
GC (1)	GC0000183A (fr)
HK (1)	HK1044942B (fr)
HR (1)	HRP20010604A2 (fr)
HU (1)	HUP0200139A3 (fr)
IL (2)	IL144851A0 (fr)
JO (1)	JO2254B1 (fr)
MA (1)	MA26773A1 (fr)
MY (1)	MY122630A (fr)
NO (1)	NO320099B1 (fr)
NZ (1)	NZ513370A (fr)
PL (1)	PL350428A1 (fr)
PT (1)	PT1157005E (fr)
RU (1)	RU2236402C2 (fr)
SI (1)	SI1157005T1 (fr)
TR (1)	TR200102489T2 (fr)
WO (1)	WO2000050401A1 (fr)
YU (1)	YU59901A (fr)
ZA (1)	ZA200106371B (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9928222D0 (en) *	1999-11-30	2000-01-26	Univ Sheffield	Chiral catalysts for asymmetric acylation and related transformations
AUPQ514600A0 (en)	2000-01-18	2000-02-10	James Cook University	Brain injury treatment
NZ523273A (en) *	2000-07-14	2004-08-27	F	N-oxides as NK1 receptor antagonist prodrugs of 4-phenyl-pyridine derivatives
TWI287003B (en) *	2000-07-24	2007-09-21	Hoffmann La Roche	4-phenyl-pyridine derivatives
SE0004245D0 (sv)	2000-11-20	2000-11-20	Pharmacia Ab	Novel compounds and their use
KR100846339B1 (ko) *	2000-11-20	2008-07-15	바이오비트럼 에이비(피유비엘)	세로토닌 5ｈｔ-2 수용체의 아고니스트 또는안타고니스트로서의 피페라지닐피라진 화합물
US20030083345A1 (en) *	2001-07-10	2003-05-01	Torsten Hoffmann	Method of treatment and/or prevention of brain, spinal or nerve injury
US6908935B2 (en) *	2002-05-23	2005-06-21	Amgen Inc.	Calcium receptor modulating agents
US7176322B2 (en) *	2002-05-23	2007-02-13	Amgen Inc.	Calcium receptor modulating agents
BR0314126A (pt) *	2002-09-20	2005-06-28	Pfizer Prod Inc	Ligandos de amida acìclica e sulfonamida para o receptor de estrogênio
WO2006089674A2 (fr)	2005-02-25	2006-08-31	F.Hoffmann-La Roche Ag	Comprimés présentant une dispersibilité de substance médicamenteuse améliorée
KR101331768B1 (ko)	2005-11-08	2013-11-22	버텍스 파마슈티칼스 인코포레이티드	Ａｔｐ 결합 카세트 수송체의 헤테로사이클릭 조정제
EP1954678B1 (fr) *	2005-11-30	2012-03-21	Abbott Products GmbH	Nouveaux antagonistes de nk1 et de nk2
US7671221B2 (en)	2005-12-28	2010-03-02	Vertex Pharmaceuticals Incorporated	Modulators of ATP-Binding Cassette transporters
US7754739B2 (en)	2007-05-09	2010-07-13	Vertex Pharmaceuticals Incorporated	Modulators of CFTR
AR066267A1 (es) *	2007-04-24	2009-08-05	Takeda Pharmaceutical	Derivados de piperidina como antagonistas del receptor de taquiquinina
CA2686838C (fr)	2007-05-09	2017-03-14	Vertex Pharmaceuticals Incorporated	Modulateurs de cftr
DK2639223T3 (en)	2007-12-07	2017-06-19	Vertex Pharma	Process for Preparation of Cycloalkylcarboxiamido-pyridine Benzoic Acids
HRP20170241T2 (hr)	2007-12-07	2023-03-17	Vertex Pharmaceuticals Incorporated	Čvrsti oblici 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il)ciklopropankarboksamido)-3-metilpiridin-2-il)benzojeve kiseline
NZ736561A (en)	2008-02-28	2018-02-23	Vertex Pharma	Heteroaryl derivatives as cftr modulators
KR100943878B1 (ko) *	2008-07-11	2010-02-24	오토스테크 주식회사	디지털방식 눈부심 방지 장치 및 그 제어 방법
MX2011004551A (es) *	2008-10-30	2011-05-25	Merck Sharp & Dohme	Antagonistas del receptor de orexina de isonicotinamida.
EP2501678B1 (fr) *	2009-11-17	2015-09-23	Novartis AG	Dérivés de l'arylpyridine comme inhibiteurs de l'aldosterone synthase.
DK3150198T3 (da)	2010-04-07	2021-11-01	Vertex Pharma	Farmaceutiske sammensætninger af 3-(6-(1-(2,2-difluorbenzo[d][1,3]dioxol-5-yl)-cyclopropancarboxamido)-3-methylpyriodin-2-yl)benzoesyre og indgivelse deraf
US8410107B2 (en) *	2010-10-15	2013-04-02	Hoffmann-La Roche Inc.	N-pyridin-3-yl or N-pyrazin-2-yl carboxamides
ES2671418T3 (es)	2013-11-08	2018-06-06	Kissei Pharmaceutical Co., Ltd.	Derivado de carboximetilpiperidina
RU2718044C2 (ru)	2013-11-12	2020-03-30	Вертекс Фармасьютикалз Инкорпорейтед	Способ получения фармацевтических композиций для лечения опосредованных cftr заболеваний
TWI649307B (zh)	2014-05-07	2019-02-01	日商橘生藥品工業股份有限公司	Cyclohexylpyridine derivative
HRP20211194T1 (hr)	2014-11-18	2021-10-29	Vertex Pharmaceuticals Inc.	Postupak za provođenje testova velike propusnosti putem tekućinske kromatografije visoke djelotvornosti
AU2016377658B2 (en)	2015-12-22	2022-09-29	Endosome Therapeutics, Inc.	Tripartite modulators of endosomal G protein-coupled receptors
WO2021224220A1 (fr)	2020-05-06	2021-11-11	Bayer Aktiengesellschaft	Pyridine (thio)amides en tant que composés fongicides
CN116157397B (zh)	2020-06-04	2025-07-15	拜耳公司	作为新杀真菌剂的杂环基吡啶
EP4441049A1 (fr)	2021-11-30	2024-10-09	Bayer Aktiengesellschaft	Bis(hétéro)aryl thioéther oxadiazines utilisées en tant que composés fongicides

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4174209A (en) *	1978-06-19	1979-11-13	Eli Lilly And Company	Herbicidal 1-alkyl-3-phenylpyridinium salts
US4745123A (en) *	1986-02-18	1988-05-17	Warner-Lambert Company	Substituted tetrahydro-3-pyridine-carboxylic acid, ester, and amide cholinergic agents
EP0532515B1 (fr) *	1990-05-31	1996-10-23	Pfizer Inc.	Preparation de piperidines substituees
IL111960A (en)	1993-12-17	1999-12-22	Merck & Co Inc	Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them
NZ277839A (en)	1993-12-29	1998-01-26	Merck Sharp & Dohme	Substituted morpholine derivatives, preparation and pharmaceutical compositions thereof
TW385308B (en)	1994-03-04	2000-03-21	Merck & Co Inc	Prodrugs of morpholine tachykinin receptor antagonists
NO309272B1 (no) *	1995-03-24	2001-01-08	Takeda Chemical Industries Ltd	Cykliske forbindelser, preparater inneholdende forbindelsene samt mellomprodukter for fremstilling av forbindelsene
US5972938A (en)	1997-12-01	1999-10-26	Merck & Co., Inc.	Method for treating or preventing psychoimmunological disorders

2000
- 2000-02-15 JP JP2000600984A patent/JP4068305B2/ja not_active Expired - Fee Related
- 2000-02-15 YU YU59901A patent/YU59901A/sh unknown
- 2000-02-15 WO PCT/EP2000/001223 patent/WO2000050401A1/fr not_active Ceased
- 2000-02-15 CA CA002364662A patent/CA2364662C/fr not_active Expired - Fee Related
- 2000-02-15 AT AT00909174T patent/ATE280158T1/de not_active IP Right Cessation
- 2000-02-15 HU HU0200139A patent/HUP0200139A3/hu unknown
- 2000-02-15 SI SI200030546T patent/SI1157005T1/xx unknown
- 2000-02-15 TR TR2001/02489T patent/TR200102489T2/xx unknown
- 2000-02-15 KR KR10-2001-7010731A patent/KR100437587B1/ko not_active Expired - Fee Related
- 2000-02-15 CN CNB008042322A patent/CN1134417C/zh not_active Expired - Fee Related
- 2000-02-15 CZ CZ20013047A patent/CZ20013047A3/cs unknown
- 2000-02-15 RU RU2001125893/04A patent/RU2236402C2/ru not_active IP Right Cessation
- 2000-02-15 IL IL14485100A patent/IL144851A0/xx active IP Right Grant
- 2000-02-15 PT PT00909174T patent/PT1157005E/pt unknown
- 2000-02-15 HR HR20010604A patent/HRP20010604A2/hr not_active Application Discontinuation
- 2000-02-15 AU AU31549/00A patent/AU772446B2/en not_active Ceased
- 2000-02-15 NZ NZ513370A patent/NZ513370A/xx unknown
- 2000-02-15 DE DE60015089T patent/DE60015089T2/de not_active Expired - Lifetime
- 2000-02-15 DK DK00909174T patent/DK1157005T3/da active
- 2000-02-15 HK HK02106317.1A patent/HK1044942B/zh not_active IP Right Cessation
- 2000-02-15 EP EP00909174A patent/EP1157005B1/fr not_active Expired - Lifetime
- 2000-02-15 ES ES00909174T patent/ES2230070T3/es not_active Expired - Lifetime
- 2000-02-15 PL PL00350428A patent/PL350428A1/xx not_active Application Discontinuation
- 2000-02-15 BR BR0008494-8A patent/BR0008494A/pt not_active Application Discontinuation
- 2000-02-16 US US09/505,359 patent/US6225316B1/en not_active Expired - Fee Related
- 2000-02-22 MY MYPI20000647A patent/MY122630A/en unknown
- 2000-02-22 JO JO200015A patent/JO2254B1/en active
- 2000-02-22 CO CO00012321A patent/CO5140087A1/es unknown
- 2000-02-23 AR ARP000100756A patent/AR029616A1/es not_active Application Discontinuation
- 2000-02-23 GC GCP2000535 patent/GC0000183A/en active
2001
- 2001-08-02 ZA ZA200106371A patent/ZA200106371B/en unknown
- 2001-08-09 IL IL144851A patent/IL144851A/en not_active IP Right Cessation
- 2001-08-23 NO NO20014098A patent/NO320099B1/no unknown
- 2001-08-23 MA MA26301A patent/MA26773A1/fr unknown

Also Published As

Publication number	Publication date
ZA200106371B (en)	2002-11-04
WO2000050401A1 (fr)	2000-08-31
SI1157005T1 (en)	2005-02-28
DE60015089D1 (de)	2004-11-25
CZ20013047A3 (cs)	2002-02-13
IL144851A0 (en)	2002-06-30
CO5140087A1 (es)	2002-03-22
JP2002537382A (ja)	2002-11-05
JP4068305B2 (ja)	2008-03-26
HK1044942B (zh)	2004-05-28
BR0008494A (pt)	2002-02-05
ATE280158T1 (de)	2004-11-15
AR029616A1 (es)	2003-07-10
NO20014098D0 (no)	2001-08-23
AU772446B2 (en)	2004-04-29
YU59901A (sh)	2005-07-19
HUP0200139A3 (en)	2003-01-28
CN1134417C (zh)	2004-01-14
ES2230070T3 (es)	2005-05-01
DK1157005T3 (da)	2005-02-14
EP1157005A1 (fr)	2001-11-28
PL350428A1 (en)	2002-12-16
CN1341100A (zh)	2002-03-20
NO20014098L (no)	2001-08-23
PT1157005E (pt)	2005-02-28
CA2364662C (fr)	2009-10-20
TR200102489T2 (tr)	2002-04-22
CA2364662A1 (fr)	2000-08-31
NZ513370A (en)	2004-02-27
KR20010102347A (ko)	2001-11-15
RU2236402C2 (ru)	2004-09-20
HRP20010604A2 (en)	2002-08-31
IL144851A (en)	2006-08-20
HK1044942A1 (en)	2002-11-08
EP1157005B1 (fr)	2004-10-20
US6225316B1 (en)	2001-05-01
MY122630A (en)	2006-04-29
KR100437587B1 (ko)	2004-06-30
GC0000183A (en)	2006-03-29
AU3154900A (en)	2000-09-14
JO2254B1 (en)	2004-10-07
HUP0200139A2 (en)	2002-06-29
DE60015089T2 (de)	2006-02-16
NO320099B1 (no)	2005-10-24

Publication	Publication Date	Title
MA26773A1 (fr)	2004-12-20	Derives de 3-phenylpyridine et leur utilisation comme recepteurs antagonistes nk-1
FR15C0049I2 (fr)	2016-02-12	Dérivés de 4-phenylpyridine et leur utilisation comme antagonistes du recepteur NK-1
PT940391E (pt)	2004-12-31	Derivados de quinolina como antagonistas do receptor de taquicinina nk3
PT842945E (pt)	2003-07-31	Novos heterociclos como inibidores da adesao de leucocitos e antagonistas da vla-4
FR13C0001I2 (fr)	2013-11-01	Derives de quinuclidine et leur utilisation comme ligands des recepteurs m3 muscariniques
SI1170288T1 (en)	2004-12-31	Diphenylureum derivatives and their use as alpha2/5-HT2c antagonists
CU23032A3 (es)	2005-03-22	Derivados de acilguanidina como inhibidores de reabsorcion osea y como antagonistas de receptores de vitronectina.
PT1216239E (pt)	2004-05-31	Derivados de piperazina como antagonistas de 5-ht1b
PT1226131E (pt)	2004-05-31	Derivados de isoxazolecarboxamida como antagonistas do receptor adrenergico alfa1
DE60009154D1 (de)	2004-04-22	Phenylpiperazinyl-derivate
MA26907A1 (fr)	2004-12-20	Cyclohexylamines bicycliques et leur utilisation comme antagonistes de recepteurs de nmda.
EE200200135A (et)	2003-04-15	D4 antagonistidena toimivad tienoisoksasolüül- jatienüülpürrasolüülfenoksü-asendatud propüülderivaadid
PT964863E (pt)	2003-10-31	Oxazolidinonas como antagonistas de 5-ht2a
MA26236A1 (fr)	2004-08-01	Derives d'aminoquinoline et d'aminopyrridine et leur utilisation comme ligands d'adenosine a3
AU2541000A (en)	2000-08-01	Beta-phenylalanine derivatives as integrin antagonists
PT1171419E (pt)	2005-04-29	Derivados de bifenilo como antagonistas do receptor da neuroquinina-1
DZ3367A1 (fr)	2001-12-13	Derives de 2-aminothiazoline et leur utilisation comme inhibiteurs de no-synthase
NO20015237L (no)	2001-12-21	Integrinreseptor-antagonister
SE514398E (sv)	2003-04-15	Förfarande vid spetsdragning
EP1139913A4 (fr)	2002-09-11	Composition et formulations et leur utilisation comme nociceptifs, anti-anxiolytiques et anabolisants
NO20021249L (no)	2002-05-10	Tienoisoksazolfenoksyusubstituerte etyl- og propylderivater anvendbare som D4antagonister
DZ3366A1 (fr)	2001-12-13	Derives de 4,5-dihydro-thiazol-2-ylamine et leur utilisation comme inhibiteurs de no synthase
HUP0201540A3 (en)	2002-12-28	Serotomin and 5ht1a receptor antagonist phenoxypropylamine derivatives and use thereof